Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Prof Christopher Butler
+44 (0)1865 289670
christopher.butler@phc.ox.ac.uk


Dr Nguyen Tran
None provided
ecraid-base@phc.ox.ac.uk


Prof Christopher Butler
+44 (0)1865 289670
christopher.butler@phc.ox.ac.uk


More information about this study, what is involved and how to take part can be found on the study website.

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A long-term observational study evaluating the presentation and management of acute respiratory tract infections in primary care across Europe

A long-term observational study evaluating the presentation and management of acute respiratory tract infections in primary care across Europe

Recruiting

Open to: All Genders

Age: All

Medical Conditions

Observation of early presentation and management of acute respiratory illness in the community


This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.


Acute respiratory infection (ARI) is the commonest reason for consulting in community care. Furthermore, new and re-emerging pathogens are often first noticed in primary care (PC). The POS-ARI-PC study is a long-term study, with the aim of describing the nature of ARI in adults and children presenting to PC across Europe. The POS-ARI-PC study will provide critically important data on the presentation and management of ARI, and build a research-ready infrastructure for studies related to the treatment, diagnosis, and prevention of ARI in primary care settings.
POS-ARI-PC-001
This embedded study is appended to the POS-ARI-PC-Core Protocol with an SSA. This study is to estimate the overall incidences of medically-attended respiratory syncytial virus, human metapneumovirus, human parainfluenza virus and rhinovirus amongst older adults in Europe.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

19 Feb 2024 01 Mar 2026

Participation in the study will last for 28 days. Once consented to the study, a member of the study team will complete a short questionnaire collecting the participants’ names and contact information, some details about them, and the symptoms they have been experiencing. A combined throat/nose swab will be collected from the patient for study purposes.

Participants will also be asked to tell us about how they are feeling today and for the next 14 days via an online or paper daily diary. They might be telephoned to ask some questions if they are unable to complete the daily diary. Their GP will be contacted after day 28 to collect information about their consultations and hospital referrals in the 28-day period.

A small number of enrolled participants who consented (optional) to be contacted by the research team about the nested qualitative study will be invited for a process evaluation interview.


Patients of any age group with an ARI.
POS-ARI-PC-001: Patients aged 60 years and over with an ARI

You can take part if:



You may not be able to take part if:


Patients will not be eligible if:1. According to the judgement of the recruiting clinician, they will not be able to comply with study procedures, for example, because they do not understand the language in which the study is being conducted locally (and have no one to help and translate for them); have a serious psychiatric disorder; or are terminally ill2. Symptoms of presumed non-infective origin3. Participant requires admission to the hospital on the day of inclusion. Additional in/exclusion criteria might apply to embedded studies and will be described in the SSA or ISA

(added 28/02/2024)POS-ARI-PC-001 StudyAs per the POS-ARI-PC CORE Protocol, with one exception: patients needing hospitalisation can be recruited into the study if timing allows. Patients can provide a swab and decide not to participate in the follow-up procedures.


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • NIHR CRN: Thames Valley and South Midlands
    John Radcliffe Hospital Headley Way Headington
    Oxford
    OX3 9DU

Participants may not personally benefit from taking part but will help researchers and doctors learn more about the presentation and treatment of people with respiratory infections. It is not anticipated that there are any risks involved in taking part in the study.
Same as POS-ARI-PC-Core study procedures. In addition, participants who indicated in their diary not feeling recovered from the RTI will be phoned on Day 28 (+/-7 days) using the Day 28 phone questionnaire, with the same questions as the Day 14 phone questionnaire.
A small number of enrolled participants who consented (optional) to be contacted by the research team about the nested qualitative study will be invited for a process evaluation interview.

Dr Nguyen Tran
None provided
ecraid-base@phc.ox.ac.uk


Prof Christopher Butler
+44 (0)1865 289670
christopher.butler@phc.ox.ac.uk


Prof Christopher Butler
+44 (0)1865 289670
christopher.butler@phc.ox.ac.uk



More information about this study, what is involved and how to take part can be found on the study website.


The study is sponsored by European Clinical Research Alliance for Infectious Diseases (Ecraid) and funded by European Commission.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: ISRCTN10204126

Or CPMS 55487

Last updated 24 October 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.